Laquinimod Phase IIa Study in Active Crohn's Disease
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The study aims to evaluate the safety and clinical effect of daily oral treatment of
Laquinimod capsules in active moderate to severe Crohn's disease. This study will assess
Laquinimod doses of 0.5mg /day to 2 mg/day in sequential dose groups (cohorts). Laquinimod is
a novel immunomodulating drug which is currently in advanced stages of development by Teva
Pharmaceuticals Ltd. for Multiple Sclerosis.
Phase:
Phase 2
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries